TACSTD2 and Familial prostate cancer: As we demonstrated that Trop2 is a prognostic tissue biomarker for clinically significant prostate cancer and is associated with worse clinical features, suggesting the great potential of Trop2 targeted therapy as a therapeutic strategy for metastatic prostate cancer.